Recce Pharmaceuticals Ltd Stock OTC Markets
Stocks
RECEF
AU000000RCE5
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
09:33:35 2025-06-24 EDT
|
5-day change | 1st Jan Change | ||
| 0.2200 USD | -56.00% |
|
-.--% | - |
| 08-31 | Recce Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 08-30 | Recce Pharmaceuticals Ltd Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 113M 81.14M 69.78M 65.84M 59.98M 112M 7.76B 784M 302M 3.93B 305M 298M 12.5B | P/E 2027 * |
-4.35x | P/E 2028 * | 3.33x |
|---|---|---|---|---|---|
| Enterprise Value | 138M 99.04M 85.17M 80.36M 73.21M 137M 9.47B 957M 368M 4.8B 372M 364M 15.25B | EV / Sales 2027 * |
11.1x | EV / Sales 2028 * | 1.2x |
| Free-Float |
62.73% | Yield 2027 * |
-
| Yield 2028 * | - |
| 1 day | -56.00% |
| 3 years | 0.22 |  | 0.6 |
| 5 years | 0.22 | | 0.6 |
| 10 years | 0.22 | | 0.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 2020-08-27 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 2020-09-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 2012-09-30 |
James Graham
BRD | Director/Board Member | - | 2012-04-30 |
| Director/Board Member | - | 2022-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -56.00% | -.--% | - | - | 78.27M | |
| -0.11% | -3.16% | +48.82% | +91.49% | 1,002B | |
| -0.27% | -4.34% | +51.52% | +65.89% | 644B | |
| +1.63% | -2.00% | +20.49% | +71.12% | 443B | |
| -0.63% | -1.06% | +28.11% | +34.59% | 343B | |
| +0.43% | -14.61% | +9.88% | +27.26% | 262B | |
| +0.93% | -1.82% | -1.82% | +8.41% | 245B | |
| -2.25% | -13.88% | +37.33% | +47.43% | 212B | |
| -0.90% | -5.09% | -15.47% | -57.75% | 199B | |
| -0.58% | -4.24% | +25.65% | +90.54% | 181B | |
| Average | -5.71% | -5.00% | +22.72% | +42.11% | 392.19B | |
| Weighted average by Cap. | +0.07% | -4.24% | +31.84% | +57.11% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 12.5M 8.96M 7.71M 7.27M 6.62M 12.38M 857M 86.6M 33.33M 435M 33.65M 32.92M 1.38B | 54.3M 38.94M 33.49M 31.6M 28.79M 53.81M 3.72B 376M 145M 1.89B 146M 143M 6B |
| Net income | -25.1M -18M -15.48M -14.61M -13.31M -24.87M -1.72B -174M -66.95M -873M -67.59M -66.11M -2.77B | 33.4M 23.95M 20.6M 19.44M 17.71M 33.1M 2.29B 231M 89.09M 1.16B 89.95M 87.98M 3.69B |
| Net Debt | 24.96M 17.9M 15.4M 14.53M 13.23M 24.74M 1.71B 173M 66.59M 868M 67.23M 65.76M 2.76B | -48.1M -34.5M -29.67M -27.99M -25.5M -47.67M -3.3B -333M -128M -1.67B -130M -127M -5.31B |
Employees
-
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
- RECEF Stock
Select your edition
All financial news and data tailored to specific country editions
